PanGenomic Health will purchase Mindleap Health for approximately $3 million. Mindleap Health is an app that connects users with mental health treatment, according to a Sept. 1 Mydecine news release.
“Given the recent narrowing of Mydecine’s business scope, we needed to find a group that we believe is capable of continuing the vision of Mindleap and taking it to the next level,” said Josh Bartch, CEO and chair of Mydecine. “We believe the PanGenomic Group is that group. Mindleap has over 40,000 organic downloads, and we believe this app has the potential to reach millions of users.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
